Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.

Pituitary · 2022 · PMC8821488 · PMID 34498217

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

There was a tendency for greater mean HbA1c increase from baseline in a subgroup receiving the dose of 60 mg than in a subgroup on pasireotide-LAR 20/40 mg, but the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.